Jazz Pharmaceuticals (JAZZ) Income towards Parent Company (2010 - 2026)

Jazz Pharmaceuticals' Income towards Parent Company history runs 16 years deep, the most recent figure standing at $293.1 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company rose 418.59% year-over-year to $293.1 million in Q1 2026; TTM through Mar 2026 was $29.7 million, a 93.85% decrease from a year earlier, with the FY2025 full-year figure at -$355.4 million, down 163.27% from the prior year.
• Income towards Parent Company rose to $293.1 million in Q1 2026 per JAZZ's latest filing, from $203.5 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $293.1 million in Q1 2026 and bottomed at -$718.4 million in Q2 2025.
• The 5-year median for Income towards Parent Company is $94.6 million (2023), against an average of $41.4 million.
• Across the five-year window, Income towards Parent Company slumped 641.44% in 2022 and soared 1116.53% in 2023, its largest moves.
• Year by year, Income towards Parent Company stood at -$240.0 million in 2022, then soared by 139.44% to $94.6 million in 2023, then surged by 102.0% to $191.1 million in 2024, then climbed by 6.47% to $203.5 million in 2025, then jumped by 44.02% to $293.1 million in 2026.
• Per Business Quant, the three latest JAZZ Income towards Parent Company figures stand at $293.1 million (Q1 2026), $203.5 million (Q4 2025), and $251.4 million (Q3 2025).